Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-25-011307
Filing Date
2025-08-13
Accepted
2025-08-13 07:47:33
Documents
86
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q adap-20250630x10q.htm   iXBRL 10-Q 1877954
2 EX-31.1 adap-20250630xex31d1.htm EX-31.1 9723
3 EX-31.2 adap-20250630xex31d2.htm EX-31.2 10466
4 EX-32.1 adap-20250630xex32d1.htm EX-32.1 6032
5 EX-32.2 adap-20250630xex32d2.htm EX-32.2 6014
  Complete submission text file 0001558370-25-011307.txt   8182414

Data Files

Seq Description Document Type Size
6 EX-101.SCH adap-20250630.xsd EX-101.SCH 57033
7 EX-101.CAL adap-20250630_cal.xml EX-101.CAL 62295
8 EX-101.DEF adap-20250630_def.xml EX-101.DEF 223875
9 EX-101.LAB adap-20250630_lab.xml EX-101.LAB 462016
10 EX-101.PRE adap-20250630_pre.xml EX-101.PRE 353948
88 EXTRACTED XBRL INSTANCE DOCUMENT adap-20250630x10q_htm.xml XML 1436680
Mailing Address 60 JUBILEE AVENUE MILTON PARK ABINGDON, OXFORDSHIRE United Kingdom
Business Address 60 JUBILEE AVENUE MILTON PARK ABINGDON, OXFORDSHIRE United Kingdom 44 1235 430000
Adaptimmune Therapeutics PLC (Filer) CIK: 0001621227 (see all company filings)

EIN.: 000000000 | State of Incorp.: X0 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37368 | Film No.: 251209018
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)